At first glance, the newest device from health-tech innovator PNOĒ looks straight out of a Hollywood blockbuster. Resembling the menacing, face-covering apparatus worn by Bane, the hulking nemesis of Batman, the mask straps securely around the back of the head, covering both the nose and mouth. However, its underlying purpose is entirely benign—and potentially revolutionary.
Designed to capture and analyze the gases of human respiration, the device measures precisely how much oxygen a user consumes and how much carbon dioxide they exhale. It then translates these intricate physiological metrics into actionable, data-driven advice regarding nutrition, physical training, and overall lifestyle optimization. As the wellness industry increasingly pivots toward proactive health and lifespan extension, PNOĒ is positioning its futuristic hardware at the vanguard of a burgeoning consumer revolution.
Main Facts: Bringing Lab-Grade Metrology to the Masses
Founded with operations spanning Malden, Massachusetts, and Athens, Greece, PNOĒ is preparing for the official global launch of its flagship product, the PNOĒ 2.0, on October 1. The defining breakthrough of this iteration lies in its accessibility: unlike its predecessor, which required a trained specialist to administer, the 2.0 model is entirely self-administered.
According to co-founder and CEO Apostolos Atsalakis, the testing process has been streamlined to absolute simplicity. A user can walk into a local gym, secure the mask, press a button, sit comfortably, and breathe naturally for eight minutes. "That’s it. It’s that easy," Atsalakis explained during a recent video call from the company’s Athens headquarters.
By eliminating the necessity of a dedicated, certified operator, the self-service format removes the primary operational bottleneck that previously restricted metabolic testing to specialized environments. This opens the door for widespread adoption across unattended fitness centers, boutique wellness clubs, and potentially even neighborhood pharmacies.
Despite its consumer-friendly interface, the technology is rooted in rigorous science. Metabolic testing—which assesses how the body converts food and oxygen into cellular energy—has been a cornerstone of exercise physiology for over a century. For decades, it has served as the gold standard for measuring VO₂ max (the maximum volume of oxygen an individual can utilize during intense exertion) and overall cardiorespiratory fitness. Historically, however, capturing these metrics demanded bulky, expensive laboratory carts found almost exclusively in university sports science departments and elite hospital wings.
PNOĒ’s value proposition is bringing clinical-grade accuracy into a sleek, portable ecosystem, paired with proprietary software that turns complex data into personalized regimens. The system captures 23 distinct biomarkers, extending far beyond standard VO₂ max to include:
- Resting Metabolic Rate (RMR): The exact number of calories the body burns at rest.
- Metabolic Flexibility: The biological efficiency with which the body switches between burning fat and carbohydrates for fuel.
Atsalakis argues that these precise metrics answer critical physiological questions that standard blood tests simply cannot address, such as hyper-personalized caloric needs and optimal athletic conditioning thresholds.
Chronology: From Cambridge Labs to Global Expansion
The trajectory of PNOĒ illustrates the evolution of modern health-tech startups, navigating academic origins, venture capital backing, and rapid market scaling over the past decade.
- Academic Origins: The enterprise traces its conceptual roots to Atsalakis’s Ph.D. research in advanced sensing technologies at the University of Cambridge. During a period when the first generation of consumer wearables was exploding in popularity, Atsalakis became fascinated by the rich, untapped physiological data hidden within human breath.
- Company Inception: Atsalakis co-founded PNOĒ alongside childhood friend Panos Papadiamantis, who currently serves as the company’s Chief Product Officer.
- The Y Combinator Era (Winter 2019): The early-stage startup was accepted into the prestigious Y Combinator accelerator batch in early 2019—at a time when "longevity science" was still a niche sector rather than the booming multi-billion-dollar industry it is today.
- Funding and Growth: Over subsequent years, PNOĒ successfully secured approximately $22 million in total venture funding. This includes a recently closed $11 million financing round supported by notable investors such as venture firm 50 Years and Google Maps co-founder Lars Rasmussen.
- The Launch of PNOĒ 2.0: Culminating years of industrial design work in collaboration with Milan-based Design Group Italia, the company is set to roll out its self-service hardware on October 1. The team reportedly went through dozens of iterative redesigns to ensure the hardware was rugged, intuitive, and reliable enough for public, unmonitored use.
Supporting Data: Market Positioning and Enterprise Integration
PNOĒ operates on a strictly B2B (business-to-business) model. Rather than selling directly to individual consumers, the company targets premium health clubs, hospitality brands, corporate wellness programs, and clinical networks, which in turn offer the test as an elevated service to their members.
Key Business Metrics and Client Ecosystem
- Enterprise Footprint: PNOĒ’s hardware and software are currently utilized by elite brands, including Equinox (where the test is featured in nearly all clubs), Four Seasons hotels, Red Bull, the National Basketball Association (NBA), the Mount Sinai Health System, and premier med-spa chain Restore Hyper Wellness.
- Geographic Distribution: Approximately 85% of PNOĒ’s revenue originates in the United States, which Atsalakis describes as "by far the most advanced market globally" for longevity and preventative health. The company is actively scaling its footprint across Europe and leveraging strategic partners in Latin America and Asia.
- Subscription Economics: Businesses subscribe to PNOĒ services at rates ranging from $400 to over $1,000 per month. This comprehensive fee includes the physical hardware, analytical software licenses, staff training modules, and co-branded marketing collateral—a turnkey package Atsalakis terms a "business in a box."
- Company Scale: PNOĒ currently employs a workforce of 110 people, has achieved corporate profitability, and boasts year-over-year revenue growth exceeding 100%. Management is preparing to open a Series B funding round within the next six to twelve months to accelerate global deployment.
The physical design of the PNOĒ 2.0 system also thoughtfully resolves post-pandemic sanitation concerns. The sensitive electronic measurement components detach seamlessly from the medical-grade silicone mask and adjustable head straps. This allows commercial venues to share expensive hardware safely among numerous clients, while each user retains personal ownership of an inexpensive, individual mask interface.
Official Responses and Regulatory Posture
Despite its clinical-grade aspirations, PNOĒ maintains a disciplined stance regarding its regulatory boundaries. The device has not received clearance from the U.S. Food and Drug Administration (FDA) as a medical diagnostic tool.
Atsalakis is unequivocal about the company’s positioning: "We do not provide medical recommendations."
Instead, PNOĒ is legally and functionally classified as a wellness and lifestyle device. Comparing it to everyday fitness technology, Atsalakis notes, "It’s like a body composition device, like a scale. A doctor cannot prescribe medication based on our results."
However, the leadership team acknowledges that the future may hold clinical applications. Academic researchers have long studied whether volatile organic compounds and metabolic byproducts in human breath can serve as early-warning biomarkers for systemic pathologies, including various forms of cancer. While Atsalakis believes that PNOĒ’s rapidly expanding repository of respiratory data could eventually aid in early health-risk detection, he concedes that achieving full diagnostic clearance is "definitely a couple of years away," with stringent regulatory hurdles stretching that horizon outward. "We’re not there yet," he stated candidly.
Implications: Navigating the Crowded Wellness Landscape
PNOĒ occupies a fascinating middle ground in the modern health ecosystem. On one end of the spectrum lie traditional, stationary metabolic carts confined to elite hospitals and research universities. On the other end are consumer smartwatches and fitness trackers—such as those from Apple, Garmin, and Whoop—which merely estimate metrics like VO₂ max using heart-rate variability algorithms, alongside consumer breath-analyzers like Lumen that focus strictly on nutritional state.
By bridging this gap, PNOĒ positions its platform as a rigorous onboarding diagnostic. Many enterprise clients integrate the test into their initial membership consultations, bridging the divide between casual fitness tracking and an exhaustive clinical medical workup.
The timing aligns perfectly with cultural shifts. Thanks to prominent longevity researchers and public figures championing cardiorespiratory fitness as a primary metric of health span, VO₂ max has transformed into a powerful buzzword. Atsalakis goes so far as to label VO₂ max the single strongest predictor of human longevity, framing his company’s diagnostic output as an essential scorecard for an increasingly health-conscious global population.
As PNOĒ prepares for its October 1 launch and looks toward an upcoming Series B financing round, the company faces the challenge of normalizing a bold, unconventional piece of fitness technology. Whether gym-goers embrace the "Bane mask" aesthetic in pursuit of optimized metabolisms remains to be seen, but the appetite for actionable, data-driven longevity solutions has never been higher.
